Literature DB >> 26946949

Comparative effectiveness of primary PCI versus fibrinolytic therapy for ST elevation myocardial infarction: a review of the literature.

Eleanor R Joy1, John Kurian2, Chris P Gale1.   

Abstract

AIM: To compare the effectiveness of primary percutaneous coronary intervention (pPCI) and fibrinolytic therapy (FL) for the acute management of ST elevation myocardial infarction (STEMI).
METHODS: A review of guidelines and PubMed literature comparing clinical outcomes of patients with STEMI treated with pPCI or FL.
RESULTS: Earlier trials reported reduced mortality and reinfarction with pPCI. Recent randomized data suggest similar outcomes for delayed pPCI compared with FL, especially in geographically remote areas. Guidelines recommend pPCI as the preferred reperfusion strategy for STEMI, if available within 120 mins of first medical contact.
CONCLUSION: pPCI is the preferred treatment strategy for STEMI. However, FL with subsequent percutaneous coronary intervention remains a viable option for those in rural areas.

Entities:  

Keywords:  ST-elevation myocardial infarction; fibrinolytic therapy; primary percutaneous coronary intervention; thrombolysis

Mesh:

Year:  2016        PMID: 26946949     DOI: 10.2217/cer-2015-0011

Source DB:  PubMed          Journal:  J Comp Eff Res        ISSN: 2042-6305            Impact factor:   1.744


  2 in total

1.  Circulating Platelet-Derived Microparticles Associated with Postdischarge Major Adverse Cardiac Events in ST-Elevation Acute Myocardial Infarction.

Authors:  Anggoro Budi Hartopo; Dyah Samti Mayasari; Ira Puspitawati; Hasanah Mumpuni
Journal:  Cardiol Res Pract       Date:  2020-07-06       Impact factor: 1.866

2.  Intravenous thrombolysis before endovascular therapy for large vessel strokes can lead to significantly higher hospital costs without improving outcomes.

Authors:  Ansaar T Rai; SoHyun Boo; Chelsea Buseman; Amelia K Adcock; Abdul R Tarabishy; Maurice M Miller; Thomas D Roberts; Jennifer R Domico; Jeffrey S Carpenter
Journal:  J Neurointerv Surg       Date:  2017-01-06       Impact factor: 5.836

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.